BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy
There was no significant difference between survival and first-line immunotherapy or first-line targeted therapy. Additional studies are required to establish whether front-line immunotherapy is linked to more effective long-term disease control compared to first-line targeted therapy.
Authors
- Giorgio Mangino (ORCID: https://orcid.org/0000-0002-8950-9780)
- Elena De Falco (ORCID: https://orcid.org/0000-0002-5220-0587)
- Antonella Calogero (ORCID: https://orcid.org/0000-0002-3322-2916)
- Claudio Di Cristofano (ORCID: https://orcid.org/0000-0003-2891-5598)
- Vincenzo Petrozza (ORCID: https://orcid.org/0000-0001-9837-8690)
- Concetta Potenza (ORCID: https://orcid.org/0000-0002-6300-8697)
- Ilaria Proietti (ORCID: https://orcid.org/0000-0003-3795-3190)
- Alessandra Spagnoli (ORCID: https://orcid.org/0000-0002-7772-3130)
- Luca Pacini
- Velia Melone
- Paolo Rosa (ORCID: https://orcid.org/0000-0002-8468-0677)
- G. Romeo (ORCID: https://orcid.org/0000-0002-7638-1001)
Institutions
- Maria Cecilia Hospital (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Melanoma Management
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1080/20450885.2024.2432826
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.23